MSKCC CAR T shows 72% response in mesothelioma

Researchers from MSKCC presented data for a mesothelin-targeted autologous CAR T cell therapy that could be the first to crack the solid tumor juggernaut for this treatment modality while also minimizing toxicity. The data could provide a read through to a preclinical allogeneic mesothelin

Read the full 440 word article

User Sign In